Mainz Biomed N.V. entered a Securities Purchase Agreement with David E. Lazar for a $6 million private placement of convertible preferred shares in two closings, with the first $3 million closing completed on February 13, 2026. Lazar was appointed as temporary non-executive director and Chair of the Board, with rights to nominate additional directors post-shareholder approval.
Key takeaways
Entered Securities Purchase Agreement with David E. Lazar on February 13, 2026 for $6M investment
Issued 3M First Closing Shares (Series A/B/C Preferred) for $3M at $1.00/share on February 13, 2026
Second Closing of 2M Series D/E Preferred Shares for $3M at $1.50/share pending Conversion Approval
Preferred Shares convertible into up to 477M Ordinary Shares, representing >95% fully diluted ownership
Appointed David E. Lazar as temporary non-executive director and Chair effective February 13, 2026
Entered Voting Agreement with stockholders owning 12.4% Ordinary Shares to support Investment proposals
Settlement Agreements with 2 officers and 3 directors for ~$1.9M payments upon Final Closing